Publications

Our R&D efforts are powered by a stellar team of scientists, who are widely respected for their expertise.

Our R&D team is home to an impressive constellation of scientists drawn from a wide array of disciplines. As experts in their field, our people regularly publish their work in prestigious journals. We also engage with the wider scientific community to conduct research and co-author papers. See below the list of publications by our people:

Hillchol^®
iNCOVACC^®
Covaxin^®
Rotavac^®
Rotavac 5D^®
Typbar^®
Typbar TCV^®
Jenvac^®
Indirab^®
Hnvac^®
Revac-B^®
Regen-D^®

1. A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol^®) in comparison to Shanchol^TM Click Here
1. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®) Click Here
1. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021 Jan 21; Click Here

2. Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021 Jul;21(7):950-61. Click Here

3. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, Aileni VK, Kanungo S, Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173-84. Click Here

4. Ganneru B, Jogdand H, Daram VK, Das D, Molugu NR, Prasad SD, et al. Th1 Skewed immune response of Whole Virion Inactivated SARS CoV 2 Vaccine and its safety evaluation. iScience. 2021 Mar;102298. Click Here

5. Mohandas S, Yadav PD, Shete-Aich A, Abraham P, Vadrevu KM, Sapkal G, et al. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. iScience. 2021 Feb;24(2):102054. Click Here

6. Yadav PD, Ella R, Kumar S, Patil DR, Mohandas S, Shete AM, et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Comm. 2021 Mar 2;12:1386. Click Here

7. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study | medRxiv [Internet]. [cited 2022 Jan 19]. Click Here

8. Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. Journal of Travel Medicine. 2021 Jun 1;28(4):taab051 Click Here

9. Yadav PD, Sapkal GN, Ella R, Sahay RR, Nyayanit DA, Patil DY, et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. Journal of Travel Medicine. 2021 Oct 11;28(7):taab104. Click Here

10. Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, et al. Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum [Internet]. Microbiology; 2021 Jan [cited 2022 Feb 25]. Click Here

11. Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, et al. Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. Clinical Infectious Diseases. 2022 Jan 15;74(2):366-8. Click Here

12. Sapkal G, Yadav PD, Ella R, Abraham P, Patil DY, Gupta N, et al. Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine. Journal of Travel Medicine. 2021 Oct 11;28(7):taab077. Click Here

13. Vadrevu KM, Ganneru B, Reddy S, Jogdand H, Raju D, Praturi U, et al. Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial [Internet]. Infectious Diseases (except HIV/AIDS); 2022 Jan [cited 2022 Feb 25]. Click Here

14. Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model. iScience. 2022 Oct 21;25(10):105178. Epub 2022 Sep 22. PMID: 36164480; PMCID: PMC9493142. Click Here

15. Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants. Frontiers in Immunology. 2023. Click Here

16. Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152 Neutralization of South Africa Variant (B.1.351) and Delta Variant (B.1.617.2) Click Here

17. Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against alpha, Beta, Delta and omicron variants of concern. J Travel Med. 2022 Mar 24:taac039. doi: 10.1093/jtm/taac039. Epub ahead of print. PMID: 35325176. Click Here

BY OTHER INSTITUTIONS:

1. Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, et al. Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine. 2021 Oct 22;39(44):6492-509. Click Here

2. Dash GC, Subhadra S, Turuk J, Parai D, Rath S, Sabat J, et al. Breakthrough SARS‐CoV‐2 infections among BBV‐152 (COVAXIN®) and AZD1222 (COVISHIELDTM) recipients: Report from the eastern state of India. J Med Virol. 2021 Oct 13;10.1002/jmv.27382. Click Here

3. Yadav PD, Sahay RR, Sapkal G, Nyayanit D, Shete AM, Deshpande G, et al. Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152. J Travel Med. 2021 Sep 28;taab154. Click Here

4. Desai D, Khan AR, Soneja M, Mittal A, Naik S, Kodan P, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. Lancet Infect Dis. 2022 Mar;22(3):349-56. Click Here

5. Kant R, Dwivedi G, Zaman K, Sahay RR, Sapkal G, Kaushal H, et al. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin. J Travel Med. 2021 Oct 15;taab166. Click Here

6. Vikkurthi R, Ansari A, Pai AR, Jha SN, Sachan S, Pandit S, et al. Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern [Internet]. Infectious Diseases (except HIV/AIDS); 2021 Nov [cited 2022 Feb 25]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.11.14.21266294 Click Here

7. Kumar NP, Banurekha VV, C. P. GK, Nancy A, Padmapriyadarsini C, Mary AS, et al. Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses. Front Immunol. 2021 Oct 15;12:752397. Click Here

8. Malhotra S, Mani K, Lodha R, Bakhshi S, Mathur VP, Gupta P, et al. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. JAMA Netw Open. 2022 Jan 4;5(1):e2142210-e2142210. Click Here

9. Parai D, Choudhary HR, Dash GC, Sahoo SK, Pattnaik M, Rout UK, et al. Single-dose of BBV-152 and AZD1222 increases antibodies against spike glycoprotein among healthcare workers recovered from SARS-CoV-2 infection. Travel Med Infect Dis. 2021;44:102170. Click Here
1. Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, Appaiahgari MB, et al. A Dose-Escalation Safety and Immunogenicity Study of Live Attenuated Oral Rotavirus Vaccine 116E in Infants: A Randomized, Double-Blind, Placebo-Controlled Trial. J INFECT DIS. 2009 Aug;200(3):421-9. Click Here

2. Ella R, Bobba R, Muralidhar S, Babji S, Vadrevu KM, Bhan MK. A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC^®, administered simultaneously with or without the buffering agent in healthy infants in India. Hum Vaccin Immunother. 2018 Apr 12;14(7):1791-9. Click Here

3. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC^® in comparison with a licensed rotavirus vaccine in healthy infants | Elsevier Enhanced Reader [Internet]. [cited 2022 Feb 25]. Click Here

4. Characterization of rotavirus strains from newborns in New Delhi, India [Internet]. [cited 2022 Feb 25]. Click Here

5. Complete genome sequence analysis of candidate human rotavirus vaccine strains RV3 and 116E | Elsevier Enhanced Reader [Internet]. [cited 2022 Feb 25]. Click Here

6. Glass RI, Bhan MK, Ray P, Bahl R, Parashar UD, Greenberg H, et al. Development of Candidate Rotavirus Vaccines Derived from Neonatal Strains in India. J INFECT DIS. 2005 Sep;192(s1):S30-5 Click Here

7. Praharaj I, Platts-Mills JA, Taneja S, Antony K, Yuhas K, Flores J, et al. Diarrheal Etiology and Impact of Coinfections on Rotavirus Vaccine Efficacy Estimates in a Clinical Trial of a Monovalent Human–Bovine (116E) Oral Rotavirus Vaccine, Rotavac, India. Clinical Infectious Diseases. 2019 Jul 2;69(2):243-50 Click Here

8. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life | Elsevier Enhanced Reader [Internet]. [cited 2022 Feb 25]. Click Here

9. Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, et al. Efficacy of a Monovalent Human-Bovine (116E) Rotavirus Vaccine in Indian Infants: A Randomised Double Blind Placebo Controlled Trial. Lancet. 2014 Jun 21;383(9935):2136-43. Click Here

10. Ramani S, Stewart CJ, Laucirica DR, Ajami NJ, Robertson B, Autran CA, et al. Human milk oligosaccharides, milk microbiome and infant gut microbiome modulate neonatal rotavirus infection. Nat Commun. 2018 Nov 27;9:5010. Click Here

11. Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC^® and ROTAVAC 5D^® in Zambian infants | Elsevier Enhanced Reader [Internet]. [cited 2022 Feb 25]. Click Here

12. Hai NM, Dung ND, Pho DC, Son VT, Hoan VN, Dan PT, et al. Immunogenicity, safety and reactogenicity of ROTAVAC® in healthy infants aged 6–8 weeks in Vietnam. Vaccine. 2021 Feb 12;39(7):1140-7. Click Here

13. Debellut F, Jaber S, Bouzya Y, Sabbah J, Barham M, Abu-Awwad F, et al. Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC. PLoS One. 2020 Feb 5;15(2):e0228506. Click Here

14. Reddy SN, Nair NP, Tate JE, Thiyagarajan V, Giri S, Praharaj I, et al. Intussusception after Rotavirus Vaccine Introduction in India. N Engl J Med. 2020 Nov 12;383(20):1932-40. Click Here

15. Das MK, Arora NK, Bonhoeffer J, Zuber PLF, Maure CG. Intussusception in Young Children: Protocol for Multisite Hospital Sentinel Surveillance in India. Methods Protoc. 2018 Mar 22;1(2):11. Click Here

16. INCLEN Intussusception Surveillance Network Study Group. Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: A self-controlled case series analysis. Vaccine. 2020/09/21 ed. 2021 Jan 3;39(1):78-84. Click Here

17. Chandola TR, Taneja S, Goyal N, Antony K, Bhatia K, More D, et al. ROTAVAC^® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial. Heliyon. 2017 May;3(5):e00302. Click Here

18. Bhandari N, Sharma P, Glass RI, Ray P, Greenberg H, Taneja S, et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: Results of a randomised controlled trial. Vaccine. 2006 Jul 26;24(31):5817-23. Click Here

19. Bhan MK, Glass RI, Ella KM, Bhandari N, Boslego J, Greenberg HB, et al. Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development. The Lancet. 2014 Jun 21;383(9935):2180-3. Click Here

20. Kumar D, Beach NM, Meng X-J, Hegde NR. Use of PCR-based assays for the detection of the adventitious agent porcine circovirus type 1 (PCV1) in vaccines, and for confirming the identity of cell substrates and viruses used in vaccine production. Journal of Virological Methods. 2012 Jan 1;179(1):201-11. Click Here

21. Intussusception in Young Children: Protocol for Multisite Hospital Sentinel Surveillance in India. Methods Protoc. 2018, 1(2), 11. Click Here

22. Pecenka C, Debellut F, Bar-Zeev N, Anwari P, Nonvignon J, Shamsuzzaman M, et al. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines. Vaccine. 2018 Nov 26;36(49):7472–8. Click Here

23. 3. Lusvan ME, Debellut F, Clark A, Demberelsuren S, Otgonbayar D, Batjargal T, et al. Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia. Vaccine. 2019 Feb 4;37(6):798–807. Click Here

24. Rennert W, Hindiyeh M, Allahham M, Mercer LD, Hamad KI, Ghuneim NI, et al. Introducing ROTAVAC® to the occupied Palestinian Territories: Impact on diarrhea incidence, rotavirus prevalence and genotype composition. Vaccine. 2023 Jan 23;41(4):945–54. Click Here

25. Debellut F, Tang K, Clark A, Pecenka C, Assao B, Guindo O, et al. Impact and cost-effectiveness of rotavirus vaccination in Niger: a modelling study evaluating alternative rotavirus vaccines. BMJ Open. 2022 Oct 5;12(10):e061673. Click Here
1. Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants Click Here
1. Sabitha P, Prabha Adhikari MR, Chowdary A, Prabhu M, Soofi M, Shetty M, et al. Comparison of the immunogenicity and safety of two different brands of Salmonella typhi Vi capsular polysaccharide vaccine. Indian J Med Sci. 2004 Apr;58(4):141-9. Click Here
PUBLICATIONS BY BBIL

1. Venkatesan R, A. Praveen Kumar and V.K. Srinivas. "A challenge study to assess the protective efficacy of typhoid Vi-Polysaccharide-protein conjugate vaccine in laboratory animals". INT J CURR SCI 2011, 1: 45-49. Click Here

2. Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015 Aug 1;61(3):393-402. doi: 10.1093/cid/civ295. Epub 2015 Apr 13. PMID: 25870324. Click Here

3. Vadrevu KM, Raju D, Rani S, Reddy S, Sarangi V, Ella R, Javvaji B, Mahantshetty NS, Battu S, Levine MM. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV^®) vaccine up to 7 years following primary vaccination of children ≤2 years of age with, or without, a booster vaccination. Vaccine. 2021 Oct 29;39(45):6682-6690. doi: 10.1016/j.vaccine.2021.07.073. Epub 2021 Oct 5. PMID: 34625288. Click Here

4. Safety, immunogenicity, and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV^®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children. Click Here

5. Raghu Reddy, Bhargav Reddy, Vamshi Sarangi, Siddharth Reddy, Raches Ella & Krishna Mohan Vadrevu (2021) A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV^®) in India, Human Vaccines & Immunotherapeutics, DOI: 10.1080/21645515.2021.1947761. Click Here

6. Gao F, Lockyer K, Logan A, Davis S, Bolgiano B, Rijpkema S, Singh G, Prasad SD, Dondapati SP, Sounkhla GS. Evidence of Extended Thermo-Stability of Typhoid Polysaccharide Conjugate Vaccines. Microorganisms. 2021 Aug 11;9(8):1707. doi: 10.3390/microorganisms9081707. PMID: 34442786; PMCID: PMC8400138. Click Here

7. Baliban SM, Allen JC, Curtis B, Amin MN, Lees A, Rao RN, Naidu G, Venkatesan R, Rao DY, Mohan VK, Ella KM, Levine MM, Simon R. Immunogenicity and Induction of Functional Antibodies in Rabbits Immunized with a Trivalent Typhoid-Invasive Nontyphoidal Salmonella Glycoconjugate Formulation. Molecules. 2018 Jul 17;23(7):1749. doi: 10.3390/molecules23071749. PMID: 30018230; PMCID: PMC6099966. Click Here

PUBLICATIONS BY OTHER INSTITUTIONS

Human Challenge Study

1. Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, Harris V, Gardner J, Nebykova A, Kerridge SA, Hill J, Thomaides-Brears H, Blohmke CJ, Yu LM, Angus B, Pollard AJ. “Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial”. Lancet. 2017 Dec 2;390(10111):2472-2480. doi: 10.1016/S0140-6736(17)32149-9. Epub 2017 Sep 28. Click Here

Navi Mumbai

2. Longley AT, Date K, Luby SP, Bhatnagar P, Bentsi-Enchill AD, Goyal V, Shimpi R, Katkar A, Yewale V, Jayaprasad N, Horng L, Kunwar A, Harvey P, Haldar P, Dutta S, Gidudu JF. Evaluation of Vaccine Safety After the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018. Clin Infect Dis. 2021 Aug 16;73(4):e927-e933. doi: 10.1093/cid/ciab059. PMID: 33502453; PMCID: PMC8366822. Click Here

3. Jayaprasad N, Borhade P, LeBoa C, Date K, Joshi S, Shimpi R, Andrews JR, Luby SP, Hoffman SA. Retrospective Review of Blood Culture-Confirmed Cases of Enteric Fever in Navi Mumbai, India: 2014-2018. Am J Trop Med Hyg. 2023 Aug 7;109(3):571-574. doi: 10.4269/ajtmh.23-0102. PMID: 37549903; PMCID: PMC10484249. Click Here

4. Hoffman SA, LeBoa C, Date K, Haldar P, Harvey P, Shimpi R, An Q, Zhang C, Jayaprasad N, Horng L, Fagerli K, Borhade P, Daruwalla S, Dharmapalan D, Gavhane J, Joshi S, Rai R, Rathod V, Shetty K, Warrier DS, Yadav S, Chakraborty D, Bahl S, Katkar A, Kunwar A, Yewale V, Andrews JR, Bhatnagar P, Dutta S, Luby SP. Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India. Clin Infect Dis. 2023 Jul 5;77(1):138-144. doi: 10.1093/cid/ciad132. PMID: 36947143; PMCID: PMC10320126. Click Here

5. Megan E Carey, Gateway to Typhoid Conjugate Vaccine Introduction in India and Beyond—Programmatic Effectiveness of a Public Sector Typhoid Conjugate Vaccine Campaign in Navi Mumbai, Clinical Infectious Diseases, Volume 77, Issue 1, 1 July 2023, Pages 145–147. Click Here

Malawi

6. Patel PD, Patel P, Liang Y, Meiring JE, Misiri T, Mwakiseghile F, Tracy JK, Masesa C, Msuku H, Banda D, Mbewe M, Henrion M, Adetunji F, Simiyu K, Rotrosen E, Birkhold M, Nampota N, Nyirenda OM, Kotloff K, Gmeiner M, Dube Q, Kawalazira G, Laurens MB, Heyderman RS, Gordon MA, Neuzil KM; TyVAC Malawi Team. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. N Engl J Med. 2021 Sep 16;385(12):1104-1115. doi: 10.1056/NEJMoa2035916. PMID: 34525285; PMCID: PMC8202713. Click Here

7. Liang Y, Driscoll AJ, Patel PD, Datta S, Voysey M, French N, Jamka LP, Henrion MYR, Ndeketa L, Laurens MB, Heyderman RS, Gordon MA, Neuzil KM. Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data. Lancet Glob Health. 2023 Jan;11(1):e136-e144. doi: 10.1016/S2214-109X(22)00466-1. Epub 2022 Nov 25. PMID: 36442498; PMCID: PMC9748309. Click Here

8. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial - The Lancet Global Health [Internet]. [cited 2022 Oct 20]. Click Here

9. Patel PD, Liang Y, Meiring JE, Chasweka N, Patel P, Misiri T, Mwakiseghile F, Wachepa R, Banda HC, Shumba F, Kawalazira G, Dube Q, Nampota-Nkomba N, Nyirenda OM, Girmay T, Datta S, Jamka LP, Tracy JK, Laurens MB, Heyderman RS, Neuzil KM, Gordon MA; TyVAC team. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. Lancet. 2024 Jan 25:S0140-6736(23)02031-7. doi: 10.1016/S0140-6736(23)02031-7. Click Here

Bangladesh

10. Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas PK, Bhuiyan AI, Ahmmed F, Colin-Jones R, Smith N, Tonks S, Voysey M, Mujadidi YF, Mazur O, Rajib NH, Hossen MI, Ahmed SU, Khan A, Rahman N, Babu G, Greenland M, Kelly S, Ireen M, Islam K, O'Reilly P, Scherrer KS, Pitzer VE, Neuzil KM, Zaman K, Pollard AJ, Clemens JD. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet. 2021 Aug 21;398(10301):675-684. doi: 10.1016/S0140-6736(21)01124-7. Epub 2021 Aug 9. PMID: 34384540; PMCID: PMC8387974. Click Here

11. Tadesse BT, Khanam F, Ahmmed F, Im J, Islam MdT, Kim DR, et al. Prevention of Typhoid by Vi Conjugate Vaccine and Achievable Improvements in Household Water, Sanitation, and Hygiene: Evidence From a Cluster-Randomized Trial in Dhaka, Bangladesh. Clinical Infectious Diseases. 2022 Apr 12;ciac289. Click Here

Burkina Faso

12. Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono AB, Nébié I, Konaté AT, Berges GD, Diarra A, Ouedraogo M, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Neuzil KM, Laurens MB. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. Int J Infect Dis. 2021 Jan;102:517-523. doi: 10.1016/j.ijid.2020.10.103. Epub 2020 Nov 8. PMID: 33176205; PMCID: PMC7762715. Click Here

13. Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono A, Nébié I, Konaté A, Berges GD, Diarra A, Ouedraogo M, Bougouma EC, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Oshinsky JJ, Pasetti MF, Neuzil KM, Laurens MB. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. Int J Infect Dis. 2021 Jul;108:465-472. doi: 10.1016/j.ijid.2021.05.061. Epub 2021 Jun 1. PMID: 34082090; PMCID: PMC8298254. Click Here

14. Ouedraogo A, Diarra A, Nébié I, Barry N, Kabore JM, Tiono AB, Datta S, Liang Y, Mayo I, Oshinsky JJ, Tracy JK, Girmay T, Pasetti MF, Jamka LP, Neuzil KM, Sirima SB, Laurens MB. Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso. J Pediatric Infect Dis Soc. 2023 Sep 27;12(9):513-518. doi: 10.1093/jpids/piad058. PMID: 37589596; PMCID: PMC10533206. Click Here

Nepal

15. Shakya M, Colin-Jones R, Theiss-Nyland K, Voysey M, Pant D, Smith N, Liu X, Tonks S, Mazur O, Farooq YG, Clarke J, Hill J, Adhikari A, Dongol S, Karkey A, Bajracharya B, Kelly S, Gurung M, Baker S, Neuzil KM, Shrestha S, Basnyat B, Pollard AJ; TyVAC Nepal Study Team. “Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal”. N Engl J Med. 2019 Dec 5;381(23):2209-2218. doi: 10.1056/NEJMoa1905047. Click Here

16. Shakya M, Voysey M, Theiss-Nyland K, Colin-Jones R, Pant D, Adhikari A, Tonks S, Mujadidi YF, O'Reilly P, Mazur O, Kelly S, Liu X, Maharjan A, Dahal A, Haque N, Pradhan A, Shrestha S, Joshi M, Smith N, Hill J, Clarke J, Stockdale L, Jones E, Lubinda T, Bajracharya B, Dongol S, Karkey A, Baker S, Dougan G, Pitzer VE, Neuzil KM, Shrestha S, Basnyat B, Pollard AJ; TyVAC Nepal Team. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health. 2021 Nov;9(11):e1561-e1568. doi: 10.1016/S2214-109X(21)00346-6. PMID: 34678198; PMCID: PMC8551681. Click Here

Pakistan

17. Qamar FN, Yousafzai MT, Khaliq A, et al. Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan. Vaccine. 2020;38(19):3518-3523. doi:10.1016/j.vaccine.2020.03.028. Click Here

18. Yousafzai MT, Karim S, Qureshi S, Kazi M, Memon H, Junejo A, Khawaja Z, Ur Rehman N, Ansari MS, Ali R, Ujjain IU, Lohana HM, Memon NM, Hussain M, Nigar R, Bar-Zeev N, Qamar FN. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. Lancet Glob Health. 2021 Aug;9(8):e1154-e1162. doi: 10.1016/S2214-109X(21)00255-2. PMID: 34297962; PMCID: PMC8315145. Click Here

19. Batool R, Tahir Yousafzai M, Qureshi S, Ali M, Sadaf T, Mehmood J, Ashorn P, Naz Qamar F. Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study. Vaccine. 2021 Sep 24;39(40):5858-5865. doi: 10.1016/j.vaccine.2021.08.051. Epub 2021 Aug 28. Erratum in: Vaccine. 2022 Apr 6;40(16):2471. PMID: 34465474. Click Here

Zimbabwe

20. Lightowler MS, Manangazira P, Nackers F, Van Herp M, Phiri I, Kuwenyi K, et al. Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: A matched case control study. Vaccine. 2022 Jul 29;40(31):4199–210. Click Here

Others

21. Rijpkema S, Hockley J, Logan A, et al. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. Biologicals. 2018;56:29–38. doi:10.1016/j.biologicals.2018.09.001. Click Here

22. Voysey M, Pollard AJ. Seroefficacy of Vi Polysaccharide- Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV)”. Clin Infect Dis. 2018 Jun 18;67(1):18-24. doi: 10.1093/cid/cix1145. Click Here

23. Lee EY, Park JY, Kim DR, Song M, Sahastrabuddhe S, Kim H, Chon Y, Yang JS. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT). PLoS Negl Trop Dis. 2020 Mar 23;14(3):e0008171. doi: 10.1371/journal.pntd.0008171. PMID: 32203521; PMCID: PMC7156108. Click Here

24. Johnson Mari, Stockdale Lisa, de Haan Noortje, Wuhrer Manfred, Pollard Andrew J.et al. Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination. Frontiers in Tropical Diseases VOLUME 2 2021 DOI=10.3389/fitd.2021.742804 ISSN=2673-7515. Click Here
1. Singh A, Mitra M, Sampath G, Venugopal P, Rao JV, Krishnamurthy B, et al. A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains. J Infect Dis. 2015 Sep 1;212(5):715-25. Click Here

2. Hegde NR, Gore MM. Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother. 2017 Feb 22;13(6):1320-37. Click Here

3. Vadrevu KM, Potula V, Khalatkar V, Mahantshetty NS, Shah A, Ella R. Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine. J Infect Dis. 2019 Dec 20;222(9):1478-87. Click Here
1. Ravish HS, Sudarshan MK, Madhusudana SN, Annadani RR, Narayana DHA, Belludi AY, et al. Assessing safety and immunogenicity of post-exposure prophylaxis following interchangeability of rabies vaccines in humans. Hum Vaccin Immunother. 2014 Feb 28;10(5):1354–8. Click Here

2. Sampath G, Madhusudana SN, Sudarshan MK, Ashwathnarayana DH, Mahendra BJ, Ullas TP, et al. Immunogenicity and safety study of Indirab: A Vero cell based chromatographically purified human rabies vaccine. Vaccine. 2010 May 28;28(24):4086–90. Click Here
1. Hegde NR, Kumar D, Rao PP, Kumari PK, Kaushik Y, Ravikrishnan R, et al. Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India. Vaccine. 2014 Jun 17;32(29):3636–43. Click Here

2. Basavaraj VH, Sampath G, Hegde NR, Mohan VK, Ella KM. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine. 2014 Jul 31;32(35):4592–7. Click Here
1. Lakshmi G, Reddy PS, Kumar KR, Bhavani NV, Dayanand M. Study of the safety, immunogenicity and seroconversion of a hepatitis-B vaccine in malnourished children of India. Vaccine. 2000 Apr 3;18(19):2009–14. Click Here
1. A Phase III Study to Evaluate the Safety and Efficacy of Recombinant Human Epidermal Growth Factor (REGEN-DTM 150) in Healing Dia. Wounds [Internet]. 2006 Jul 1 [cited 2022 Feb 25] Click Here

2. Efficacy of Recombinant Human Epidermal Growth Factor (Regen-D 150) in Healing Diabetic Foot Ulcers: A Hospital-Based Randomized Controlled Trial - Vijay Viswanathan, Udyama Juttada, Mary Babu, 2020 [Internet]. [cited 2022 Feb 25]. Click Here

3. Recombinant human epidermal growth factor (REGEN-DTM 150): Effect on healing of diabetic foot ulcers - Diabetes Research and Clinical Practice [Internet]. [cited 2022 Feb 25]. Click Here

4. Chairmandurai AR, Kanappa SV, Vadrevu KM, Putcha UK, Venkatesan V. Recombinant Human Epidermal Growth Factor Alleviates Gastric Antral Ulcer Induced by Naproxen: A Non-steroidal Anti Inflammatory Drug. Gastroenterology Res. 2010 Jun;3(3):125-33. Click Here

+ -

Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. We seek to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets.

Quick Links

Our Products

© 2022 Bharat Biotech. All Rights Reserved.